Mitoxantrone and intermediate-dose cytosine arabinoside for poor risk acute leukemias: response to treatment and factors influencing outcome.

J Sierra, A Grañena, F Bosch, E Carreras, JM Martí, A Urbano-Ispizua, M Rovira, C. Rozman

Research output: Contribution to journalArticleResearch

7 Citations (Scopus)
Original languageEnglish
Pages (from-to)301-309
JournalHematol Oncol
Issue number6
Publication statusPublished - 1 Jan 1992

Cite this